Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02933905

Enrollment

Registered

2016-10-14

Start date

2014-01-31

Completion date

2016-06-30

Last updated

2016-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-VEGF Treatment, Diabetic Macular Edema, Vitreomacular Interface

Brief summary

Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors

Interventions

DRUGIntravitreal Ranibizumab injection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* diabetic macular edema treatable with antiangiogenic drugs

Exclusion criteria

* age under 18 * cardiovascular events during the last year * previous vitrectomy * previous macular edema treatment during the last 4 months

Design outcomes

Primary

Measure	Time frame
Change in best-corrected visual acuity	One year

Secondary

Measure	Time frame
Change in central macular thickness	One year
Number of ranibizumab injections	One year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026